Twenty five percent of the prostate cancer patients with a TNM≥3 were heterozygous for the CYP3A4 variant and had an OR of 3.16 compared to the *1A/*1A genotype, but this difference was not statistically significant (p = 0.10) (Table S3). Here, CYP3A4 is linked to prostate carcinoma.